Bavarian Nordic

Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm. The company has a research and development facility in Martinsried, Germany, and offices in Zug, Switzerland, and Morrisville, North Carolina. The company uses viral vectors in its research and development.

Bavarian Nordic A/S
Company typePublic
Traded as
  • Nasdaq Copenhagen: BAVA
  • OMXC25CAP component
OTC Markets: BVNRY
ISINDK0015998017
IndustryBiotechnology
Founded1994 (1994)
HeadquartersPhilip Heymans Alle 3 DK-2900 Hellerup,
Hellerup
,
Denmark
Key people
  • Luc Debryune (chairman)
  • Paul Chaplin (president and CEO)
ProductsImvanex, Imvamune, Jynneos, Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Mvabea
Revenue 7.062 billion kr. (2023)
Total assets 14.373 billion kr. (2023)
Total equity 10.340 billion kr. (2023)
Number of employees
 1.379 (2023)
Websitewww.bavarian-nordic.com
Footnotes / references
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.